ERBB2 and breast cancer: When using the glycoEnzymes as the universe for enrichment tests instead of the entire transcriptome, several GlycoEnzOnto pathways were found to be downregulated in Her2+ breast cancer including (i) lactosylceramide synthesis, (ii) O-GalNAc glycosylation and (iii) glycan capping (Fig. 4C).